Efficacy of Apremilast in Patients with Psoriasis with Limited Skin Involvement, Including High-Impact Site Involvement: A Pooled Analysis of Six Trials - Summary - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Effectiveness of Apremilast in Individuals with Psoriasis Exhibiting Minimal Skin Involvement and High-Impact Area Affected: A Combined Analysis of Six Clinical Trials
To evaluate the efficacy of apremilast in patients with plaque psoriasis exhibiting limited skin involvement (affected body surface area 3–10%) and high-impact site symptoms.
Approach:
Study Design: Pooled analysis of six clinical trials, including five randomized, double-blind, placebo-controlled studies and one single-arm, open-label study.
Endpoints: Evaluated outcomes at weeks 16 and 32, including BSA thresholds, PASI, sPGA, and DLQI responses.
Statistical Analysis: Combined results from trials using nonresponder imputation for binary endpoints and mixed-effects models for continuous measures.
Key Findings:
By week 16, apremilast improved skin clearance and quality of life in patients with limited skin involvement (affected body surface area 3–10%) and high-impact site symptoms.
Benefits were sustained through week 32.
Apremilast is effective for patients with psoriasis affecting high-impact sites.
Interpretation:
Apremilast is presented as a systemic treatment option for individuals with limited plaque psoriasis, including those with high-impact site involvement.
Limitations:
The analysis is based on data from clinical trials, which may not fully represent real-world patient populations.
Potential biases inherent in trial designs and patient selection.
Conclusion:
Apremilast demonstrates efficacy in improving symptoms and quality of life for patients with limited plaque psoriasis and high-impact site involvement.
by Bruce Strober, Mark Lebwohl, Peter van de Kerkhof, Linda Stein Gold, Joseph F. Merola, Yukari Okubo, Paolo Gisondi, Zhenwei Zhou, Siddharth Chaudhari, Cynthia Deignan, Ulrich Mrowietz
Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.
Investigational inhibitor was not associated with treatment-related serious adverse events and produced biomarker changes consistent with pathway inhibition in healthy volunteers.
